You can buy or sell IMV and other stocks, options, ETFs, and crypto commission-free!
IMV Inc. Common Shares, also called IMV, is a clinical-stage biopharmaceutical company, which engages in the research and development of immunotherapies for the treatment of infectious diseases. Read More Its proprietary drug delivery platform DPX develops a pipeline of novel therapeutic and preventive approaches for cancer and other serious diseases. The company was founded by Warwick Kimmins and Brian E. Lowe on March 28, 2000 and is headquartered in Dartmouth, Canada.
Dartmouth, Nova Scotia
52 Week High
52 Week Low
Financial PostMar 25
IMV to Announce Fourth Quarter and Full Year 2019 Financial and Operational Results and Host Investor Conference Call and Webcast on March 31, 2020
DARTMOUTH, Nova Scotia — IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of i
— per share
Expected Nov 6, Pre-Market